|
|
|
|
|
|
|
|
abstract
OBJECTIVE: To evaluate whether hormone therapy (HT) after
nonserous epithelial ovarian cancer is associated with a decrease in
overall and disease-free survival.
METHODS: We conducted a retrospective cohort study. The
Manitoba Cancer Registry and Drug Programs Information Network were
searched to find all women with known nonserous epithelial ovarian,
fallopian tube, or primary peritoneal cancer between 1995 and 2010 who
had used HT after treatment. Women who did not receive treatment or had
no follow-up were excluded.
RESULTS: Three hundred ninety-one patients met the
inclusion criteria. Seventeen patients were excluded because the
patients did not receive treatment for cancer, and 17 were excluded for
lack of follow-up. A total of 94 women received HT after treatment, and
263 women did not. The average age was 57.8 years. In HT users younger
than 55 years of age, disease-free survival is improved according to
both the multivariable landmark analysis (n=68/145, and the
time-varying Cox regression analysis (n=42/158, when adjusting for International
Federation of Gynecology and Obstetrics stage and need for chemotherapy.
There is no statistical difference in overall survival in this age
group. No associations between HT use and overall survival or
disease-free survival were found among women aged 55 years and older.
CONCLUSION: After treatment for nonserous epithelial
ovarian cancer, hormone therapy is not associated with decreased
disease-free or overall survival.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.